Vaccine compositions

a technology of compositions and vaccines, applied in the field of vaccine compositions, can solve the problems of affecting the health system, affecting the treatment and prevention of allergic airways diseases, and the direct and indirect costs and achieve the effect of preventing or suppressing the onset of allergic airways diseases

Inactive Publication Date: 2011-04-21
NEWCASTE INNOVATION LTD
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0017]The treatment or prevention may prevent or

Problems solved by technology

In addition to being potentially debilitating for sufferers, the direct and indirect costs of allergic airways diseases on health systems are substantial.
Together these patho-physiological manifestations lead to symptoms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine compositions
  • Vaccine compositions
  • Vaccine compositions

Examples

Experimental program
Comparison scheme
Effect test

example 1

Mouse Model of Th2-Induced Allergic Airways Diseases

[0093]The present inventors have established an experimental model of allergic airways disease in BALB / c mice (Th2 and IgE responding), based on sensitization consistency and subsequent challenge with ovalbumin (OVA). This model is described in co-pending International PCT Application No. PCT / AU2007 / 001098, the disclosure of which is incorporated herein in its entirety.

[0094]Briefly, female BALB / c mice (6-8 week old) were obtained from the Central Animal House, University of Newcastle. For the induction of allergic airways disease, mice were sensitized by intraperitoneal injection of OVA (50 ug; Sigma, Missouri, USA) at day 0 using OVA in Rehydrogel (1 mg, Reheis, Berkeley Heights, USA) in sterile saline (200 μl) and mice were subsequently challenged by intranasal droplet application of OVA (day 12-15; 10 ug, 50 ul sterile saline).

[0095]For the experiments described in the subsequent examples, whole killed Streptococcus pneumoniae ...

example 2

Effect of Vaccination Using Streptococcus pneumoniae Capsular Polysaccharide and Exotoxoid on the Development of Allergic Airways Diseases

[0102]Streptococcus pneumoniae (Type 3, strain NC012695; available under Accession Number ACTC6303 from the National Collection of Type Cultures, Egham, UK) was provided by Professor J. Kyd of the University of Can berra, Australia. Bacteria were cultured and prepared as described in Preston et al (2007). Briefly, prior to use, bacteria were stored at −80° C. in tryptone soya broth (TSB, Oxoid Australia) with 5% defibrinated horse blood, 0.5% glucose and 20% glycerol. Bacteria were freshly cultured before experiments on tryptone soy agar supplemented with 5% blood and 0.5% glucose and incubated for 16 hours (37° C., 5% CO2). Colonies were harvested, and suspended in phosphate buffered saline (PBS). Ethanol-killed Streptococcus pneumoniae were prepared and stored at −80° C. until required.

[0103]Pneumolysoid was obtained from Professor James Paton o...

example 3

Effect of Vaccination Using Streptococcus pneumoniae Capsular Polysaccharide, Exotoxoid, Cell Walls, CpG Oliguncleotides, and Combinations Thereof, on the Development of Allergic Airways Diseases

[0108]The inventors have also investigated the effect of the addition of purified cell walls from unencapsulated Streptococcus pneumoniae and of bacterial CpG oligonucleotides on BALF eosinophil levels and Th2 cytokine (IL-5 and IL-13) production. Four components (T3P, Ply, purified cell walls (CW) and CpG oligonucleotides (CpG)) were administered, alone, in combination, and in all possible pairwise and triplet combinations. Experiments were conducted as described above in Example 2.

[0109]Streptococcus pneumoniae cell walls were purified as described (Tuomanen et al., 1985) with minor modifications. Briefly, unencapsulated Streptococcus pneumoniae R6 (ATCC BAA-255) was cultured overnight in Heart Infusion (HI) media to 5×108 cfu / ml. Following centrifugation and supernatant removal, bacteria ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Immunogenicityaaaaaaaaaa
Strain pointaaaaaaaaaa
Antigenicityaaaaaaaaaa
Login to view more

Abstract

The present invention provides methods for the treatment or prevention of allergic airways diseases, the suppression of allergic immune responses, and the induction protective immunity against allergic airways diseases wherein the methods comprise administering to subjects in need thereof an effective amount of a Streptococcus pneumoniae capsular polysaccharide and a Streptococcus pneumoniae exotoxin or exotoxoid, optionally together with one or more additional antigenic or immunomodulatory constituents, components or fractions of Streptococcus pneumoniae and/or immunopotentiators. Administration of individual components is also contemplated. Also provided are vaccine compositions suitable for use in accordance with methods disclosed herein.

Description

FIELD OF THE INVENTION[0001]The present invention relates generally to methods for the treatment and prevention of allergic airways diseases such as asthma. More particularly the invention relates to the immunization of individuals using vaccines and / or therapies based on constituents of Streptococcus pneumoniae and to the use of such vaccines and / or therapies for the treatment or prevention of allergic airways diseases.BACKGROUND OF THE INVENTION[0002]Allergic airways diseases such as asthma and allergic rhinitis are of major, and increasing, public health concern, especially in industrialised nations where they represent the most common chronic disorders in children. Asthma, in particular, is a chronic respiratory disorder that has increased alarmingly in prevalence in the last 20 years. Australia has one of the highest rates of asthma in the world, with estimates suggesting that up to 10-20% of the population are affected. Worldwide up to one in four children, one in seven adoles...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/09A61K31/715A61K38/02A61P37/08A61P37/04A61P11/06A61P11/14A61P11/00A61P7/10
CPCA61K2039/55561A61K39/092A61P11/00A61P11/06A61P11/14A61P37/00A61P37/04A61P37/08A61P7/10
Inventor GIBSON, PETERHANSBRO, PHILIP
Owner NEWCASTE INNOVATION LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap